LEO Pharma announces changes to its Global Leadership Team
Ballerup, August 28, 2023 - Today, LEO Pharma announced the appointment of Nathalie Daste as new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023.
Nathalie Daste brings extensive experience in organization design, transformation and capability building in the healthcare sector. Over the past decade, she has led a number of large-scale initiatives focused on building a distinctive culture and driving organizational performance for large companies in the pharma and industrial sectors. Nathalie has a proven track record at a global level at Novartis and McKinsey & Company where she started her career. She was recently Chief People Officer, Global Head Strategy & Commercial Excellence at CENTOGENE (NASDAQ:CTNG).
In her new role, Nathalie Daste will head LEO Pharma’s Global People function as well as Corporate Affairs, including sustainability and ESG. She succeeds Dennis Schmidt Pedersen, who has decided to step down from his role and leave LEO Pharma after six years in the company.
Nathalie Daste holds an MBA from INSEAD, France, and a master’s degree in management from ESSEC, France. She is French and will be relocating to Denmark with her family.
Christophe Bourdon, CEO of LEO Pharma, commented:
“I am looking very much forward to welcoming Nathalie Daste to the LEO Pharma family. Her vast experience from global life-science makes her a catch for LEO Pharma as we have been looking for a successor to Dennis Schmidt Pedersen. Nathalie brings a strong external view and experience from developing and leading people to LEO Pharma. With her joining the Global Leadership team, we can ensure these insights are brought into strategy. I would like to thank Dennis for everything he has done for LEO Pharma. We are in a good place today because of him. I wish him all the best of success in his next endeavour.”
Nathalie Daste said:
“I am truly excited to be joining LEO Pharma and becoming part of the amazing journey the company is on, helping people suffering from skin diseases. Having spent much time in Denmark with my family, I have experienced the Danish way of life and culture at close hand, and I look very much forward to relocating here and becoming part of it.”
Dennis Schmidt Pedersen commented:
“During my six years with LEO Pharma, my team and I together took a decentralized HR delivery model and globalized it in a highly effective process. I am leaving a very skilled and high-performing Global People organization fully aligned with LEO Pharma’s strategy. I am confident that the global team will continue to solidify the model. After shaping and executing a significant transformation in the people space, I have now decided to start a new chapter in my work-life outside LEO Pharma. I want to thank my amazing team for all the great moments we have shared.”
--ENDS--
Kontakter
Henrik Heskjær
Tlf:+45 3140 6180hdtdk@leo-pharma.comAbout LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,600 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma announces changes to its Global Leadership Team4.7.2024 14:10:00 CEST | Pressemeddelelse
LEO Pharma today announced that Nathalie Daste, Executive Vice President of Global People & Corporate Affairs, has decided to resign her position and leave LEO Pharma due to personal reasons. Christophe Bourdon, CEO of LEO Pharma, said: “I want to express heartfelt gratitude to Nathalie for her dedication to the journey we are currently on. In the Global Leadership Team, we will miss Nathalie, her engagement, and her fresh ideas, but I fully understand the need to put family first.” Nathalie Daste said: “It is with mixed emotions that I share the news of my departure from this remarkable organization. Due to unforeseen family circumstances, I have made the difficult decision to step away from my role. While it is hard to bid farewell to such a talented and dedicated team, I am confident that the organization will continue to thrive and achieve great things.” Effective immediately, Michael Meyer, currently Head of HR Business Partnering and an experienced HR leader, will step in until a
LEO Pharma announces topline results of phase 3 trial in China for Enstilar® (LEO 90100) demonstrating superiority in adult Chinese subjects with stable plaque psoriasis7.5.2024 20:00:00 CEST | Pressemeddelelse
Enstilar® (LEO 90100) showed superiority over Daivobet® ointment in primary and both secondary endpoints in the testing hierarchy showing improved efficacy in reducing the severity and extent of stable plaque psoriasis. Overall, both Daivobet ointment and Enstilar – each of them LEO Pharma products – were well tolerated. Safety profiles were consistent with previous trial findings and as expected with no new safety concerns identified. The trial is a commitment of LEO Pharma’s expanding presence in China, making a fundamental difference for Chinese patients living with psoriasis through additional treatment options. Enstilar – a unique cutaneous foam formulation built on the active ingredients of Daivobet – is a global market leader in topical psoriasis.
Solid start to the year: 13% revenue growth driven by strong performance in dermatology3.5.2024 09:00:00 CEST | Pressemeddelelse
Q1 2024 Trading Update (Unaudited): In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage asset to LEO Pharma’s medical dermatology pipeline, and delgocitinib for chronic hand eczema (CHE) is on track for its planned European launch in Q4 2024. Full-year outlook has been revised slightly upwards.
Annual report 2023: LEO Pharma delivers 10% revenue growth and returns to positive EBITDA29.2.2024 14:00:00 CET | Pressemeddelelse
Ballerup, February 29, 2024. – LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement. LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.
LEO Pharma announces positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE)24.1.2024 08:00:00 CET | Pressemeddelelse
Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events. DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.1 With only one treatment option currently approved for severe CHE and no approved optionsfor more moderate forms of the disease, there is a considerable unmet need for patients living with CHE.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum